List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 370 studies with search of: Open Studies | "Sarcoma"
Include studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Recruiting Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
Conditions: Neuroblastoma;   Ewings Sarcoma;   Osteogenic Sarcoma;   Rhabdomyosarcoma;   Synovial Sarcoma
Intervention: Biological: Autologous dendritic cell vaccine with adjuvant
2 Recruiting Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
Conditions: Sarcoma;   Soft Tissue Sarcoma;   Locally Advanced Sarcoma;   Unresectable Sarcoma;   Metastatic Sarcoma
Intervention: Drug: Bevacizumab, Gemcitabine, docetaxel and valproic acid
3 Recruiting Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
Conditions: Metastatic Soft Tissue Sarcoma;   Locally Advanced Soft Tissue Sarcoma;   Unresectable Soft Tissue Sarcoma
Interventions: Drug: INNO-206;   Drug: Doxorubicin
4 Not yet recruiting Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Hemangiopericytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Synovial Sarcoma;   Dermatofibrosarcoma Protuberans;   Stage II Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: pazopanib hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Other: placebo;   Procedure: therapeutic conventional surgery;   Radiation: external beam radiation therapy;   Other: pharmacological study;   Other: laboratory biomarker analysis
5 Recruiting Autologous T Cells, Low-Dose Recombinant Interferon Gamma, Cyclophosphamide, and Low-Dose Aldesleukin in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
Conditions: Adult Liposarcoma;   Adult Synovial Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Biological: recombinant interferon gamma;   Biological: aldesleukin;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Biological: NY-ESO-1-specific T lymphocytes
6 Recruiting Bevacizumab and Radiation Therapy for Sarcomas
Conditions: Soft Tissue Sarcoma;   Fibrous Histiocytoma;   Liposarcoma;   Leiomyosarcoma;   Fibrosarcoma;   Synovial Sarcoma
Interventions: Drug: Bevacizumab;   Procedure: Radiation Therapy
7 Recruiting Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Conditions: Sarcoma;   Leiomyosarcoma;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Fibrous;   Histiocytoma/Undifferentiated Pleomorphic Sarcoma
Intervention: Drug: Gemcitabine and Docetaxel in Combination with Pazopanib
8 Recruiting Continuing vs Intermittent Trabectedin-regimen in Patients With Advanced Soft Tissue Sarcoma Experiencing Response or Stable Disease After the 6th Cycle
Conditions: Soft Tissue Sarcoma;   Uterine Sarcoma
Interventions: Drug: Trabectedin;   Other: Drug-holiday
9 Recruiting Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Conditions: Non-rhabdomyosarcoma Soft Tissue Sarcoma;   Bone Sarcoma
Intervention: Radiation: Proton Beam Radiation
10 Not yet recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus;   Other: laboratory biomarker analysis;   Biological: DEC-205-NY-ESO-1 fusion protein vaccine
11 Recruiting Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Conditions: Solid Tumor;   Adult Central Nervous System Germ Cell Tumor;   Adult Rhabdomyosarcoma;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Soft Tissue Sarcoma;   Ewing Sarcoma;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Ovarian Mixed Germ Cell Tumor;   Previously Untreated Childhood Rhabdomyosarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Extragonadal Germ Cell Tumor;   Recurrent Extragonadal Non-seminomatous Germ Cell Tumor;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Neuroblastoma;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: busulfan;   Drug: melphalan;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation;   Other: pharmacological study;   Procedure: autologous bone marrow transplantation
12 Recruiting A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall
Conditions: Soft Tissue Sarcoma;   Non Metastatic Disease
Interventions: Drug: doxorubicin , ifosfamide;   Drug: doxorubicin, ifosfamide
13 Recruiting Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Conditions: Brain and Central Nervous System Tumors;   Kidney Cancer;   Sarcoma
Interventions: Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate
14 Recruiting Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Drug: everolimus;   Drug: imatinib mesylate;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis
15 Recruiting Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
Condition: Sarcoma
Interventions: Biological: cixutumumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis
16 Recruiting Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure;   Other: medical chart review
17 Recruiting Lenalidomide in Treating Patients With AIDS-Related Kaposi Sarcoma
Conditions: Nonneoplastic Condition;   Sarcoma
Interventions: Drug: lenalidomide;   Other: laboratory biomarker analysis
18 Recruiting Study of Blood Samples From Patients With Ewing Sarcoma and Their Relatives
Condition: Sarcoma
Intervention: Other: laboratory biomarker analysis
19 Recruiting Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Condition: Sarcoma
Interventions: Drug: bortezomib;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
20 Unknown † Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma
Condition: Kaposi's Sarcoma
Intervention: Drug: Indinavir in association with Vinblastina +/- Bleomicina

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services